Revelation Biosciences, Inc. (REVBW) stock
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Revelation Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Revelation Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$9.33M. For fiscal 2025 it was -$8.27M. The highest annual figure on record is -$216.66K in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.27M | – |
| FY2024 | Dec 31, 2024 | -$18.32M | – |
| FY2023 | Dec 31, 2023 | -$7.29M | – |
| FY2022 | Dec 31, 2022 | -$11.22M | – |
| FY2021 | Dec 31, 2021 | -$11.09M | – |
| FY2020 | Dec 31, 2020 | -$216.66K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$947.47K | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.73M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.59M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.38M | -16314.4% |
| Q4 FY2020 | Dec 31, 2020 | -$208.12K | – |
| Q3 FY2020 | Sep 30, 2020 | -$868 | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.37K | – |
| Q1 FY2020 | Mar 31, 2020 | $14.69K | – |